Piscataway, NJ, United States

Enzon Pharmaceuticals

www.enzon.com
Piscataway, NJ, United States

Time filter

Source Type

News Article | May 16, 2017
Site: marketersmedia.com

— Factors such as rising government and corporate financial support in the industry, growing awareness of fungal infections and increase in disposable income are fueling the market growth. However, generic competition and huge diffusion of conventional drugs used for the treatment of fungal infections are hampering the market growth. Cost of drugs and their effectiveness in treatment are major challenges in the market. Dermatophytosis segment is anticipated to hold the largest market share during the forecast period due to increasing prevalence of skin infections in children. Candidiasis segment is expected to grow at the highest CAGR during the forecast period. North America is anticipated to account for the largest market share owing to the huge patient awareness levels and increased R&D spending pertaining to new drug development. Asia Pacific is expected to grow at the highest CAGR during the forecast period owing to rising awareness towards personal safety and health care. Some of the key players in Antifungal Drugs market include GlaxoSmithKline, Agilent Technologies, Inc., Kramer Laboratories, Bayer Healthcare, Abbott Laboratories, Novartis, Glenmark Pharmaceuticals Ltd, Merck & Co. Inc.,Pfizer Inc., Enzon Pharmaceuticals, PerkinElmer, Inc., Alternaria, Sigma-Aldrich and Astellas Pharma Inc. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 6 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com


Patent
Santaris Pharma and Enzon Pharmaceuticals | Date: 2013-04-30

The invention provides the combination use of antisense oligomers targeting androgen receptor mRNA and androgen receptor binding inhibitors that reduce androgen receptor activity for the treatment of androgen receptor related medical disorders, such as cancers, particularly prostate cancers and breast cancers.


Patent
Santaris Pharma and Enzon Pharmaceuticals | Date: 2012-06-22

The invention relates to oligomer compounds (oligomers), which target HER3 mRNA in a cell, leading to reduced expression of HER3 and/or HER2 and/or EGFR. Reduction of HER3 and/or HER2 and/or EGFR expression is beneficial for a range of medical disorders, such hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of HER3 and/or HER2 and/or EGFR using said oligomers, including methods of treatment.


Patent
Enzon Pharmaceuticals and Santaris Pharma | Date: 2011-04-04

The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5-(T_(x))G_(x)G_(x)c_(s)a_(s)a_(s)g_(s)c_(s)a_(s)t_(s)c_(s)c_(s)T_(x)G_(x)T-3 and 5-(G_(x))T_(x)a_(s)c_(s)t_(s)g_(s)c_(s)c_(s)t_(s)t_(s)c_(s)T_(x)T_(x)A-3, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript s designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript x designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g. diabetic retinopathy, macular degeneration (ARMD), psoriasis, rheumatoid arthritis and other inflammatory diseases.


Patent
Santaris Pharma and Enzon Pharmaceuticals | Date: 2012-12-21

Oligonucleotides directed against the hypoxia-inducible factor-1 (HIF-1) gene are provided for modulating the expression of HIF-1. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1. Methods of using these compounds for modulation of HIF-1 expression and for the treatment of diseases associated with the hypoxia-inducible factor-1 are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.


Patent
Santaris Pharma and Enzon Pharmaceuticals | Date: 2011-09-14

The invention relates to oligomer compounds (oligomers), which target beta-catening mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.


Patent
Santaris Pharma and Enzon Pharmaceuticals | Date: 2012-05-22

Oligonucleotides directed against the hypoxia-inducible factor-1 (HIF-1) gene are provided for modulating the expression of HIF-1. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1. Methods of using these compounds for modulation of HIF-1 expression and for the treatment of diseases associated with the hypoxia-inducible factor-1 are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.


Patent
Enzon Pharmaceuticals and Dana-Farber Cancer Institute | Date: 2013-02-15

The disclosure relates to oligonucleotide compounds (oligomers) that target Myc mRNA in a cell, leading to reduced expression of Myc. Reduction of Myc expression is beneficial for the treatment of certain disorders, such as hyperproliferative disorders (e.g., cancer). The disclosure provides therapeutic compositions comprising oligomers and methods for modulating the expression of Myc using said oligomers, including methods of treatment.


A method of treating a resistant or refractory cancer in a mammal includes administering an effective amount of a compound of to the mammal. In preferred aspects, the cancer is resistant or refractory to CPT-11 or CPT therapy.


Patent
Enzon Pharmaceuticals | Date: 2011-04-15

The present invention relates to polymeric conjugates of adenine nucleoside analogs. In particular, the invention relates to multi-arm polyethylene glycol conjugates of adenine nucleoside analogs and use thereof. The present invention, more specifically, provides polymeric conjugates of toyocamycin and its derivatives. Furthermore, the present invention provides a method for preparing the polymeric conjugates of adenine nucleoside analogs and a method of using the same for treating a cancer, inhibiting the growth or proliferation of cancer cells, treating a viral infection, treating a disease or condition associated with abnormal expression of VEGF. Most polymeric conjugates of toyocamycin was stable in PBS but released toyocamycin in vivo to provided inhibition of cancer cell growth.

Loading Enzon Pharmaceuticals collaborators
Loading Enzon Pharmaceuticals collaborators